Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

727.02 -18.93 (-2.54%)
Streaming Delayed Price Updated: 2:20 PM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
83 84 Next >
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
WHY: NEW YORK, NY - (NewMediaWire) - March 01, 2024 - Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Altimmune,... 
Via TheNewswire.com
Why Novo Nordisk Stock Topped the Market Today
A favorite of both investors and analysts gets a boost from a bullish move by a pundit. 
Via The Motley Fool
Record-High S&P 500 Propels SPY ETF To $500-Billion Milestone, Nvidia Tops $2 Trillion, Broadcom Surpasses Tesla
U.S. stock market continues bull run, hitting record highs for S&P 500 and Nasdaq 100. SPY ETF surpasses $500 billion AUM, with other companies also reaching milestones. 
Via Benzinga
Topics ETFs Stocks
Exposures US Equities
Eli Lilly's Commercial Moat, Competitor Landscape: BofA Emphasizes Strength in Incretin Space, Undervalued Assets
Eli Lilly: BofA Securities rates it a top pick in Biopharma, with a YTD performance of +29%. Analysts highlight undervalued opportunities in heart disease, sleep apnea, and liver disease. Price target... 
Via Benzinga
A Closer Look at 18 Analyst Recommendations For Eli Lilly and Co
Via Benzinga
$1000 Invested In This Stock 10 Years Ago Would Be Worth $13,000 Today
Via Benzinga
Stock Market Rally At Highs After Big Earnings, Inflation Data: Weekly Review
The Nasdaq is on the cusp of setting a record high. 
Via Investor's Business Daily
Topics Economy
Exposures Interest Rates
Eli Lilly Stock And The Road To 1,000: Weight-Loss Drugs Could Generate $81 Billion
Wall Street isn't properly taking into account Lilly's next-generation drugs, an analyst says. 
Via Investor's Business Daily
3 Stocks Showing Constructive Pullbacks with Indexes at New Highs
As the market becomes extended on AI exuberance, leading stocks like MongoDB, Eli Lilly and Adobe are pulling back, potentially offering new buy opportunities. 
Via MarketBeat
Topics Artificial Intelligence ETFs
Exposures Artificial Intelligence
3 Healthcare Stocks That Have Outperformed Nvidia Since 2022
The healthcare sector is no slouch when it comes to top-performing growth stocks. 
Via The Motley Fool
Got $200? 2 Dividend Stocks to Buy and Hold Forever
Trust these two real estate stocks to be attractively priced and proven performers. 
Via The Motley Fool
2 Stocks That Could Turn $1,000 Into $2,500 in 5 Years
It will take a lot, but this goal isn't out of reach for these stocks. 
Via The Motley Fool
The Hot List: 3 AI Stocks Worth Buying on Weakness
Firms using AI directly can be great picks for long-term investors, such as these three AI stocks to buy on weakness. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
These 4 Stocks Are the "Magnificent Seven" of Healthcare
Their growth trajectories aren't as meteoric, but they're still notable. 
Via The Motley Fool
Ozempic, Wegovy Other Weight-Loss Drugs Won't Solve Global Obesity Crisis Affecting 1B People, WHO Warns
The World Health Organization has cautioned that the increasing global obesity crisis, which now affects over a billion people, cannot be resolved by the use of obesity medications alone. 
Via Benzinga
The Best And Worst Performing Stocks Of February 2024
The average S&P 500 stock rose 3.87% in February even though the index itself was up more than 5%. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Top Stocks Not Named Nvidia You Need To Know About In 2024: Here's What Investors Think About Them (Wall Street Vs. Reddit)
Nvidia Corp. is one of the leading top stocks with 60% gain in 2024, but other lesser-known names have outperformed. 
Via Benzinga
5 Investors Betting Big on Weight Watchers (WW) Stock as Oprah Backs Out
WW stock is falling lower after its earnings, adding that Oprah Winfrey would step down from the board of directors. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Could These 3 Companies Headline a "Magnificent Seven" of Biotech Stocks?
These stocks meet many of the criteria long-term investors look for. 
Via The Motley Fool
Viking Therapeutics: A Teachable Moment About Investing for the Long Term
The biotherapeutics company's weight loss candidate scored a major win this week. 
Via The Motley Fool
Viking Therapeutics Just Soared 120% on Optimism About Its Weight Loss Candidate. Too Late to Buy?
Viking stock surged in the triple digits in one trading session. 
Via The Motley Fool
Is Viking Therapeutics a Buy Now?
The stock recently jumped more than 100% overnight thanks to surprising results from its anti-obesity candidate. 
Via The Motley Fool
Stock Splits Watch: 3 Likely Candidates to Keep on Your Radar in 2024
Investors should keep a close eye on these companies as rumors grow louder that stock splits are imminent. 
Via InvestorPlace
Opportunities For Investors Beyond AI And Nvidia – Biotech Breaks Out, New GDP Data Shows Inflation Pressure
To gain an edge, this is what you need to know today. 
Via Benzinga
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Interest Rates
Viking Therapeutics' Weight Loss Study Data Outperformed Novo Nordisk, Eli Lilly Studies, Analysts Say
Viking Therapeutics achieves significant weight loss in the VENTURE trial, outperforming rivals in body weight reductions. 
Via Benzinga
Large US Drug Makers Highlight Indian Market For Their Blockbuster Drugs Including For Weight Loss
Eli Lilly's CEO, David Ricks, outlines plans to launch the obesity drug Tirzepatide in India next year, presenting opportunities amid competition from Novo Nordisk. Bristol Myers Squibb expands its R&D... 
Via Benzinga
Jim Cramer Weighs In On Palo Alto, Eli Lilly And Salesforce, Says Price Target Bump For This Stock A 'Red Flag'
During Tuesday's CNBC Investing Club Morning Meeting, U.S. stocks exhibited mixed performance, prompting a closer look at prevailing market themes. Cybersecurity emerged as a key focus, with Jim Cramer... 
Via Benzinga
Why Novo Nordisk and Eli Lilly Stocks Slipped Today
A competitor to Wegovy and Zepbound might appear on pharmacy shelves before long. 
Via The Motley Fool
ALT LOSS ALERT: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
83 84 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.